Abstract: A drive system of an electric vehicle includes: an internal combustion engine; a generating motor provided so as to be able to generate electricity by receiving motive force from the internal combustion engine; and a travel motor provided so as to be able to be driven by electric power generated by the generating motor, and the drive system is configured so as to be able to switch a series hybrid mode and an engine direct connected mode, the series hybrid mode being a mode in which, while the internal combustion engine and the drive wheel are linked via a first clutch so as to be unlinkable/linkable, the travel motor and the drive wheel are linked via a second clutch different from the first clutch so as to be unlinkable/linkable, and the travel motor is used as a drive power source such that the electric vehicle travels by transmitting motive force from the travel motor to the drive wheel, the engine direct connected mode being a mode in which at least one of the internal combustion engine and the generator

Abstract: The object of the present invention is to provide a mitochondrial dysfunction improving agent comprising a vitamin K derivative having a high deliverability to mitochondria. A mitochondrial dysfunction improving agent, neurodegeneration improving agent, amyotrophic lateral sclerosis improving agent, Alzheimer's disease improving agent, and Parkinson's disease improving agent comprising at least one of a carboxylic acid ester of an active vitamin K represented by a general formula (1) or a salt thereof, and (wherein, R1 and R2 are a hydrogen atom, respectively, or a substituent selected from glycine, N-acyl glycine, N-alkyl glycine, N,N-dialkyl glycine, N,N,N-trialkyl glycine, acyl, dicarboxylic acid hemiester, and salts thereof; and at least either of R1 and R2 is glycine, N-acyl glycine, N-alkyl glycine, N,N-dialkyl glycine, N,N,N-trialkyl glycine, acyl, dicarboxylic acid hemiester, and salts thereof. R3 is a group represented by a general formula (2), or a general formula (3).

Abstract: A sputter target material which is of a sintered material, wherein the sputter target material consists of 0.5 to 50 atomic % in total of at least one metal element (M) selected from the group of Ti, Zr, V, Nb and Cr, and the balance of Mo and unavoidable impurities, and has a microstructure seen at a perpendicular cross section to a sputtering surface, in which microstructure oxide particles exist near a boundary of each island of the metal element (M), and wherein the maximum area of the island, which is defined by connecting the oxide particles with linear lines so as to form a closed zone, is not more than 1.0 mm2.

Abstract: It is intended to provide a drug which is efficacious in treating and preventing diseases wherein ischemia or an inflammatory substance associated with ischemia participates in the onset or worsening thereof. Because of containing as the active ingredient a substance selected from among farnesol, a farnesol derivative, a tocopherol derivative, a tocotrienol derivative, pharmacologically acceptable salts thereof and solvates thereof, the above-described inhibitor of ischemic disorders can exert therapeutic and preventive effects on diseases wherein ischemia or an inflammatory substance associated with ischemia participates in the onset or worsening thereof (for example, brain infarction, brain edema, cardiac infarction, etc.) not only by the administration in the acute ischemic stage but also by the therapeutic administration in subacute and/or chronic stages after ischemia-reperfusion. It is also intended to provide a farnesol carboxylic acid ester derivative and a method of producing the same.

Abstract: It is intended to provide a drug which is efficacious in treating and preventing diseases wherein ischemia or an inflammatory substance associated with ischemia participates in the onset or worsening thereof. Because of containing as the active ingredient a substance selected from among farnesol, a farnesol derivative, a tocopherol derivative, a tocotrienol derivative, pharmacologically acceptable salts thereof and solvates thereof, the above-described inhibitor of ischemic disorders can exert therapeutic and preventive effects on diseases wherein ischemia or an inflammatory substance associated with ischemia participates in the onset or worsening thereof (for example, brain infarction, brain edema, cardiac infarction, etc.) not only by the administration in the acute ischemic stage but also by the therapeutic administration in subacute and/or chronic stages after ischemia-reperfusion. It is also intended to provide a farnesol carboxylic acid ester derivative and a method of producing the same.

Abstract: A sputter target material which is of a sintered material, wherein the sputter target material consists of 0.5 to 50 atomic % in total of at least one metal element (M) selected from the group of Ti, Zr, V, Nb and Cr, and the balance of Mo and unavoidable impurities, and has a microstructure seen at a perpendicular cross section to a sputtering surface, in which microstructure oxide particles exist near a boundary of each island of the metal element (M), and wherein the maximum area of the island, which is defined by connecting the oxide particles with linear lines so as to form a closed zone, is not more than 1.0 mm2.

Abstract: A sputtering target is provided, including a target material and a backing plate that are bonded with a strong adhesion at a reduced cost. The method for bonding the target material and the backing plate does not use a special soldering material, and is therefore cheaper and more reliable. The target includes an inorganic target material and a backing plate that are bonded with a soldering material between them. At least one of the target material and the backing plate is coated with a coupling agent of a semi-metal oxide or a metal oxide.

Abstract: A sputter target material which is of a sintered material, wherein the sputter target material consists of 0.5 to 50 atomic % in total of at least one metal element (M) selected from the group of Ti, Zr, V, Nb and Cr, and the balance of Mo and unavoidable impurities, and has a microstructure seen at a perpendicular cross section to a sputtering surface, in which microstructure oxide particles exist near a boundary of each island of the metal element (M), and wherein the maximum area of the island, which is defined by connecting the oxide particles with linear lines so as to form a closed zone, is not more than 1.0 mm2.

Abstract: Disclosed is a method of producing a target material of a Mo alloy, which includes the steps of (a) preparing a green compact by compressing a raw material powder blend consisting of a Mo powder having an average particle size of not more than 20 ?m and a transition metal powder having an average particle size of not more than 500 ?m; (b) pulverizing the green compact to produce a secondary powder having an average particle size of from not less than an average particle size of the raw material powder blend to not more than 10 mm; (c) filling the secondary powder into a container for pressurizing; and (d) subjecting the secondary powder with the container for pressurizing to sintering under pressure thereby obtaining a sintered body of the target material.

Abstract: A sputtering target is provided, including a target material and a backing plate that are bonded with a strong adhesion at a reduced cost. The method for bonding the target material and the backing plate does not use a special soldering material, and is therefore cheaper and more reliable. The target includes an inorganic target material and a backing plate that are bonded with a soldering material between them. At least one of the target material and the backing plate is coated with a coupling agent of a semi-metal oxide or a metal oxide.

Abstract: The object of the present invention is to provide a tocotrienol derivative which is highly water-soluble and shows high bioavailability in the living body and &ggr;-CEHC delivering agent. (A tocotrienolcarboxylic acid ester derivative represented by the general formula (I). (wherein R2 means a carboxylic acid residue having a nitrogen substituent, and R1 and R3 mean a hydrogen atom or a methyl group.

Abstract: A resin-bonded magnet composed substantially of (a) an R—T—N-based magnetic powder having a basic composition of R&agr;T100−&agr;−&bgr;N&bgr;, wherein R is at least one selected form the group consisting of rare earth elements including Y, T is Fe or Fe and Co, 5≦&agr;≦20, and 5≦&bgr;≦30, (b) a ferrite magnetic powder having a substantially magnetoplumbite-type crystal structure and a basic composition represented by (A1−xR′x) O[(Fe1−yMy)2O3] by atomic ratio, wherein A is Sr and/or Ba, R′ is at least one selected from the group consisting of rare earth elements including Y, La being indispensable, M is Co or Co and Zn, 0.01≦x<0.4, 0.005≦y≦0.04, and 5.0≦n≦6.4, and (c) a binder. The ferrite magnet powder is preferably an anisotropic, granulated powder or an anisotropic, sintered ferrite magnet powder.

Abstract: The object of the present invention is to provide a tocotrienol derivative which is highly water-soluble and shows high bioavailability in the living body and &ggr;-CEHC delivering agent.

Abstract: The magnet powder-resin compound particles substantially composed of rare earth magnet powder and a binder resin are in such a round shape that a ratio of the longitudinal size a to the transverse size b (a/b) is more than 1.00 and 3 or less, and that an average particle size defined by (a/b)/2 is 50-300 &mgr;m. They are produced by charging a mixture of rare earth magnet powder and a binder resin into an extruder equipped with nozzle orifices each having a diameter of 300 &mgr;m or less; extruding the mixture while blending under pressure though the nozzle orifices to form substantially cylindrical, fine pellets; and rounding the pellets by rotation.

Abstract: A resin-bonded magnet composed substantially of (a) an R-T-N-based magnetic powder having a basic composition of R&agr;T100-&agr;-&bgr;N&bgr;, wherein R is at least one selected form the group consisting of rare earth elements including Y, T is Fe or Fe and Co, 5≦&agr;≦20, and 5≦&bgr;≦30, (b) a ferrite magnetic powder having a substantially magnetoplumbite-type crystal structure and a basic composition represented by (A1-xR′x)O[(Fe1-yMy)2O3] by atomic ratio, wherein A is Sr and/or Ba, R′ is at least one selected from the group consisting of rare earth elements including Y, La being indispensable, M is Co or Co and Zn, 0.01≦x≦0.4, 0.005≦y≦0.04, and 5.0≦n≦6.4, and (c) a binder. The ferrite magnet powder is preferably an anisotropic, granulated powder or an anisotropic, sintered ferrite magnet powder.

Abstract: The magnet powder-resin compound particles substantially composed of rare earth magnet powder and a binder resin are in such a round shape that a ratio of the longitudinal size a to the transverse size b (a/b) is more than 1.00 and 3 or less, and that an average particle size defined by (a/b)/2 is 50-300 &mgr;m. They are produced by charging a mixture of rare earth magnet powder and a binder resin into an extruder equipped with nozzle orifices each having a diameter of 300 &mgr;m or less; extruding the mixture while blending under pressure though the nozzle orifices to form substantially cylindrical, fine pellets; and rounding the pellets by rotation.

Abstract: A magnetically anistropic R-T-B magnet having crystal grains having aspect ratios of 2 or more and showing a substantially uniform maximum energy product distribution is produced by (a) rapidly quenching an alloy melt; (b) finely pulverizing the rapidly quenched alloy to provide magnetic powder; (c) mixing the magnetic powder with a carbon-containing additive; (d) coating the resulting mixture with a protective layer of a first lubricant such as BN substantially unreactive with the alloy components; (e) compressing it; (f) further coating the resulting compressed body with a second lubricant such as graphite or graphite+glass; and (g) further compressing it.

Abstract: A magnetically anisotropic R-T-B magnet having crystal grains having aspect ratios of 2 or more and showing a substantially uniform maximum energy product distribution is produced by (a) rapidly quenching an alloy melt; (b) finely pulverizing the rapidly quenched alloy to provide magnetic powder; (c) mixing the magnetic powder with a carbon-containing additive; (d) coating the resulting mixture with a protective layer of a first lubricant such as BN substantially unreactive with the alloy components; (e) compressing it; (f) further coating the resulting compressed body with a second lubricant such as graphite or graphite+glass; and (g) further compressing it.

Abstract: A the magnetically anisotropic magnetic powder having an average particle size of 1-1000 &mgr;m and made from a magnetically anisotropic R-TM-B-Ga or R-TM-B-Ga-M alloy having an average crystal grain size of 0.01-0.5 &mgr;m, wherein R represents one or more rare earth elements including Y, TM represents Fe which may be partially substituted by Co, B boron, Ga gallium, and M one or more elements selected from the group consisting of Nb, W, V, Ta, Mo, Si, Al, Zr, Hf, P, C and Zn. This is useful for anisotropic resin-bonded magnet with high magnetic properties.

Abstract: The magnet powder-resin compound particles substantially composed of rare earth magnet powder and a binder resin are in such a round shape that a ratio of the longitudinal size a to the transverse size b (a/b) is more than 1.00 and 3 or less, and that an average particle size defined by (a/b)/2 is 50-300 ?m. They are produced by charging a mixture of rare earth magnet powder and a binder resin into an extruder equipped with nozzle orifices each having a diameter of 300 ?m or less; extruding the mixture while blending under pressure though the nozzle orifices to form substantially cylindrical, fine pellets; and rounding the pellets by rotation.